Merck(US:MRK) Financial Modeling Prep·2026-03-12 17:04Core Viewpoint - Merck & Co., Inc. is navigating challenges in the pharmaceutical industry, particularly with its Gardasil vaccine, while maintaining a strong market position and receiving positive ratings from analysts [1][3][4]. Group 1: Stock Performance - Merck's stock closed at $117.11, reflecting a 1.14% increase from the previous close, outperforming major indexes like the S&P 500, Dow, and Nasdaq [2][4]. - The stock has shown resilience despite a prior decline of 5.04%, indicating investor confidence ahead of the upcoming earnings report [2]. Group 2: Financial Outlook - Analysts predict an earnings per share (EPS) of -$0.57 for the upcoming earnings report on April 30, 2026, representing a significant year-over-year decline of 125.68% [2]. - Revenue is expected to increase by 3.09% to $16.01 billion, indicating some growth potential despite challenges [2][4]. Group 3: Product Challenges - Merck's Gardasil vaccine sales dropped by 39% in 2025, primarily due to reduced demand in China, impacting its partnership with Zhifei and halting shipments [3]. - There is no expected rebound in Gardasil sales for 2026, which may continue to pressure Merck's revenue streams [3]. Group 4: Analyst Ratings - Wells Fargo has reaffirmed an "Overweight" rating on Merck, raising the price target to $150, reflecting optimism about the company's future performance [1][4].